Prostate Cancer

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Winning the Battle Against Prostate Cancer

After skin cancer, prostate cancer is the most common type of cancer in men in the United States. Prostate cancer can be a complex disease to treat. In some men, the disease is very aggressive and requires treatment. In others, however, it is a slow-growing disease that is unlikely to cause serious problems.

Statistics Are Abstract; Lives Aren’t

Drew Bouton, Prostate Cancer Survivor At age 45, Drew Bouton was diagnosed with stage IV prostate cancer. The late stage of his disease ruled out surgery as a treatment, but thanks to some cutting edge therapies at SCCA, Drew was able to turn back his cancer. Read more about Drew.

If you have prostate cancer, where you choose to go for initial treatment has a significant impact on the likelihood of survival. Our doctors are nationally renowned experts in treating prostate and genitourinary cancer. The SCCA team provides customized treatments for each patient, including state-of-the-art techniques such as laparoscopic da Vinci robotic surgery, ultra-precise radiotherapy techniques, and immunotherapy. In addition, there are many new medications and alternative treatments under investigation in clinical studies available only at SCCA and selected sites around the country.

Prostate Cancer Survival Rates

Below are the five-year survival rates for prostate cancer patients treated by SCCA compared to patients who were treated for prostate cancer elsewhere. This information was collected by the National Cancer Data Base (NCDB) for patients who were diagnosed and treated between 2003 and 2005 and then followed for five years. We’re only showing survival rates for patients who were diagnosed with stage II, stage III, and stage IV prostate cancer. There were not enough patients who were first diagnosed and treated at SCCA with stage 0 and stage I prostate cancer to provide meaningful results.

Stage II Prostate Cancer

  • SCCA patients are represented by the green line. Their five-year survival rate was 98 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by the yellow line. Their combined five-year survival rate was 91 percent.

Stage III Prostate Cancer

  • SCCA patients are represented by the green line. Their five-year survival rate was 96 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by the yellow line. Their five-year survival rate was 90 percent.
  • Note: While the SCCA survival rates appear to be better for stage III prostate cancer, the data could not be statistically validated.

Stage IV Prostate Cancer

  • SCCA patients are represented by the green line. Their five-year survival rate was 63 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by the yellow line. Their combined five-year survival rate was 37 percent.

The NCDB tracks the outcomes of 70 percent of all newly diagnosed cancer in the United States from more than 1,500 commission-accredited cancer programs. It has been collecting data from hospital cancer registries since 1989 and now has almost 29 million records. 

Frequently Asked Questions

Data Collection Methodology